Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3600177rdf:typepubmed:Citationlld:pubmed
pubmed-article:3600177lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0042397lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0019046lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0008551lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C1998793lld:lifeskim
pubmed-article:3600177lifeskim:mentionsumls-concept:C0052609lld:lifeskim
pubmed-article:3600177pubmed:issue1lld:pubmed
pubmed-article:3600177pubmed:dateCreated1987-7-29lld:pubmed
pubmed-article:3600177pubmed:abstractTextStroma-free hemoglobin (Hb) solutions are being developed as blood substitutes. We previously described coronary vasoconstrictor activity of Hb solutions prepared by conventional methods. In the present study we assessed the constrictor activity of unmodified and covalently modified Hb solutions purified by ATP-agarose affinity chromatography. The starting material was a red cell lysate, partially purified by ultrafiltration. Coronary constrictor activity was measured as increased perfusion pressure in isolated rabbit hearts perfused at constant coronary flow rate with buffer containing various concentrations of added Hb. The starting material increased perfusion pressure by 35 +/- 7 mmHg at 50 mg/dl. Purified Hb, retained by the affinity column, increased perfusion pressure by only 18 +/- 2 mmHg at 50 mg/dl. Hemoglobin covalently linked to ATP or pyridoxal phosphate, then purified by affinity chromatography, also had less constrictor activity than the starting material. Thus, a substance, removed by affinity chromatography but not by conventional purification, contributes to the vasoconstrictor activity of Hb solutions.lld:pubmed
pubmed-article:3600177pubmed:languageenglld:pubmed
pubmed-article:3600177pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3600177pubmed:citationSubsetIMlld:pubmed
pubmed-article:3600177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3600177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3600177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3600177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3600177pubmed:statusMEDLINElld:pubmed
pubmed-article:3600177pubmed:monthJullld:pubmed
pubmed-article:3600177pubmed:issn0024-3205lld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:ApsteinC SCSlld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:ValeriC RCRlld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:VogelW MWMlld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:HsiaJ CJClld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:ErS SSSlld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:CassidyGGlld:pubmed
pubmed-article:3600177pubmed:authorpubmed-author:BriggsL LLLlld:pubmed
pubmed-article:3600177pubmed:issnTypePrintlld:pubmed
pubmed-article:3600177pubmed:day6lld:pubmed
pubmed-article:3600177pubmed:volume41lld:pubmed
pubmed-article:3600177pubmed:ownerNLMlld:pubmed
pubmed-article:3600177pubmed:authorsCompleteYlld:pubmed
pubmed-article:3600177pubmed:pagination89-93lld:pubmed
pubmed-article:3600177pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:meshHeadingpubmed-meshheading:3600177-...lld:pubmed
pubmed-article:3600177pubmed:year1987lld:pubmed
pubmed-article:3600177pubmed:articleTitleReduced coronary vasoconstrictor activity of hemoglobin solutions purified by ATP-agarose affinity chromatography.lld:pubmed
pubmed-article:3600177pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3600177pubmed:publicationTypeIn Vitrolld:pubmed